A panel of four plasma amino acids is a promising biomarker for newly diagnosed bladder cancer

被引:3
|
作者
Liu, Zhipeng [1 ,2 ]
Teng, Chunying [1 ,4 ]
Wan, Wenting [1 ]
Wu, Fan [1 ]
Wu, Chao [1 ]
Ji, Weiping [3 ,5 ,6 ]
Shan, Yujuan [1 ,2 ]
机构
[1] Wenzhou Med Univ, Sch Publ Hlth, Dept Nutr & Food Hyg, Wenzhou 325035, Peoples R China
[2] Wenzhou Med Univ, Zhejiang Prov Key Lab Watershed Sci & Hlth, Wenzhou 325035, Peoples R China
[3] Wenzhou Med Univ, Quzhou Peoples Hosp, Dept Gen Surg, Quzhou Affiliated Hosp, Quzhou 325000, Zhejiang, Peoples R China
[4] Harbin Inst Technol, Sch Chem & Chem Engn, Dept Food Sci & Engn, Harbin 150001, Peoples R China
[5] Wenzhou Med Univ, Affiliated Hosp 2, Dept Gen Surg, Wenzhou, Zhejiang, Peoples R China
[6] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Zhejiang, Peoples R China
基金
中国国家自然科学基金;
关键词
Bladder cancer; Amino acid; Biomarker; Case-control study; METABOLISM;
D O I
10.1016/j.clnu.2024.05.003
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: Metastasis and recurrence are the main causes of death in post-operative bladder cancer (BC), emphasizing the importance of exploring early-stage diagnostic markers. Serum biomarkers constitute a promising diagnostic approach for asymptomatic stage cancer as they are non-invasive, have high accuracy and low cost. Aims: To correlate concentrations of plasma amino acids with BC progression to assess their utility as an early-stage diagnostic. Methods: Newly diagnosed BC patients (n = 95) and normal controls (n = 96) were recruited during the period from 1 December 2018 to 30 December 2020. General and food frequency questionnaires established their basic information and dietary intake data. Venous blood samples were collected from fasting subjects and used to detect levels of plasma amino acids by liquid chromatography-mass spectrometry. Verification was performed on the GSE13507 transcriptome gene expression matrix of BC from Gene Expression Omnibus (GEO) database. Results: Eleven amino acids have been identified as altered in the plasma of newly diagnosed BC patients compared to controls (P < 0.05). Adjusted by gender, education, smoking and other factors, plasma ornithine level (OR = 0.256, 95% CI: 0.104-0.630) is a protective factor for BC, plasma levels of methionine (OR = 3.460, 95% CI: 1.384-8.651), arginine (OR = 3.851, 95% CI: 1.542-9.616), and glutamate (OR = 3.813, 95% CI: 1.543-9.419) are all risk factors for BC. ROC analysis demonstrated that the combination of plasma ornithine, methionine, arginine and glutamate could accurately diagnose BC (AUC = 0.84, 95% CI: 0.747-0.833). In addition, the mRNA level of arginase 1 was decreased (P < 0.05), while the inducible nitric oxide synthase was increased significantly, which may be linked with the disturbance of arginine metabolism in BC patients. Further analysis of GEO database confirmed the role of arginine metabolism. Conclusion: A biomarker panel containing four amino acids may provide a feasible strategy for the early diagnosis of BC. However, further validation is required through prospective studies. (c) 2024 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.
引用
收藏
页码:1599 / 1608
页数:10
相关论文
共 50 条
  • [1] Comment on: A panel of four plasma amino acids is a promising biomarker for newly diagnosed bladder cancer
    Ran, Lingxiang
    Zhao, Qiancheng
    Zhao, Rui
    Hu, Guangmo
    CLINICAL NUTRITION, 2024, 43 (10) : 2346 - 2347
  • [2] A Plasma Biomarker Panel of Four MicroRNAs for the Diagnosis of Prostate Cancer
    Matin, Farhana
    Jeet, Varinder
    Moya, Leire
    Selth, Luke A.
    Chambers, Suzanne
    Clements, Judith A.
    Batra, Jyotsna
    SCIENTIFIC REPORTS, 2018, 8
  • [3] A Plasma Biomarker Panel of Four MicroRNAs for the Diagnosis of Prostate Cancer
    Farhana Matin
    Varinder Jeet
    Leire Moya
    Luke A. Selth
    Suzanne Chambers
    Judith A. Clements
    Jyotsna Batra
    Scientific Reports, 8
  • [4] A plasma biomarker panel of four microRNAs for the diagnosis of prostate cancer
    Matin, Farhana
    Jeet, Varinder
    Moya, Leire
    Selth, Luke A.
    Chambers, Suzanne
    Clements, Judith A.
    Batra, Jyotsna
    BJU INTERNATIONAL, 2018, 122 : 29 - 29
  • [5] Panel containing three serum microRNAs: a promising biomarker for early detection of bladder cancer
    Ge, Zhenjian
    Lin, Shengjie
    Lu, Chong
    Xia, Yong
    Li, Rongkang
    Li, Xinji
    Sun, Chen
    Wen, Zhenyu
    Chen, Wenkang
    Li, Yingqi
    Li, Mingyang
    Lin, Yu
    Dong, Jing
    Tao, Lingzhi
    Ji, Ling
    Lai, Yongqing
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [6] Survivin: a promising biomarker for detection and prognosis of bladder cancer
    Vitaly Margulis
    Yair Lotan
    Shahrokh F. Shariat
    World Journal of Urology, 2008, 26 : 59 - 65
  • [7] Survivin: a promising biomarker for detection and prognosis of bladder cancer
    Margulis, Vitaly
    Lotan, Yair
    Shariat, Shahrokh F.
    WORLD JOURNAL OF UROLOGY, 2008, 26 (01) : 59 - 65
  • [8] German registry for patients with newly diagnosed bladder cancer
    Geiges, G.
    Schulze, M.
    Koenig, F.
    Reinecke, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 87 - 88
  • [9] Bladder symptoms in women with newly diagnosed breast cancer
    Wong, L.
    Chung, C.
    Flores, S.
    Mortimer, J.
    CANCER RESEARCH, 2016, 76
  • [10] A Candidate Molecular Biomarker Panel for the Detection of Bladder Cancer
    Urquidi, Virginia
    Goodison, Steve
    Cai, Yunpeng
    Sun, Yijun
    Rosser, Charles J.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2012, 21 (12) : 2149 - 2158